18 F]flortaucipir allows in vivo quantification of paired helical filament tau, a core neuropathological feature of Alzheimer disease (AD), but its diagnostic utility is unclear. 
D
istinguishing Alzheimer disease (AD) dementia from other neurodegenerative disorders often poses a diagnostic challenge to clinicians due to substantial overlap in symptoms across etiological entities. 1 To facilitate the diagnostic process, the National Institute on Aging and the Alzheimer Association (NIA-AA) proposed a revised set of criteria for AD dementia that includes the possibility to use biomarkers of amyloid-β (Aβ) and neurodegeneration to support the clinical diagnosis. 2 However, Aβ pathology already starts accumulating 15 to 30 years before symptom onset. The prevalence of Aβ pathology consequently rises steeply with advancing age, which results in high rates of (comorbid) Aβ positivity in non-AD neurodegenerative disorders 3 and cognitively normal elderly individuals, 4 reducing the specificity of Aβ biomarkers. Furthermore, biomarkers reflecting neurodegeneration (eg, structural magnetic resonance imaging [MRI] ) lack specificity and often also sensitivity for AD. 5 The advent of [ 18 F]flortaucipir, a positron emission tomography (PET) tracer (currently solely used in investigational settings) with high affinity to the aggregates of tau formed in AD, 6 may resolve some of the aforementioned issues because the age-associated increase in tau aggregates in neocortex is less prevalent than that of Aβ in normal populations. 7 Initial human [ 18 F]flortaucipir PET studies have shown strong associations between regional tau and cognitive decline 8 and neurodegeneration, 9 and good discrimination between patients with AD and controls. 10, 11 However, the accuracy for distinguishing AD from non-AD neurodegenerative disorders is less clear. 
]flortaucipir PET) were not available to clinicians making the diagnosis. Controls were cognitively unimpaired and had no significant neurological or psychiatric illnesses. They were a mix of research volunteers recruited through advertisements and persons visiting the memory clinic with cognitive complaints but normal performance at neuropsychological testing (ie, "subjective cognitive decline" 18 ).
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Acquisition and Processing of PET and MRI Data
Images were acquired using previously described scanners and protocols 8, 19, 22 (eTable 3 in Supplement 1).
[ 18 F]flortaucipir PET data were locally reconstructed into 4 × 5-minute frames for the 80-to 100-minute interval after injection. Subsequently, PET images were centrally processed at Lund University using previously reported procedures 22 by analysts who were blinded to any clinical information including the clinical diagnosis. Briefly, PET images were resampled to obtain the same image size (128 × 128 × 63 matrix) and FreeSurfer (version 6.0, https://surfer.nmr.mgh.harvard .edu/) parcellation of the T1-weighted MRI scan was applied to the PET data transformed to participants' native T1-space to extract mean regional SUVR values for each participant. We performed partial volume correction using the Geometric Transfer Matrix approach 24 
Statistical Analyses
For defining accuracy, sensitivity, specificity, and positive and negative likelihood ratios, we used 2 approaches to determine tau positivity. First, we used the mean and SD in the control group and computed thresholds for all ROIs at mean+ (2 × SD non-AD neurodegenerative disorders combined, (2) AD dementia vs separate non-AD neurodegenerative disorders and controls, and (3) MCI due to AD vs the combined and separate non-AD neurodegenerative disorders and controls. We performed sensitivity analyses for the contrast AD dementia vs all non-AD neurodegenerative disorders combined using (1) partial volume-corrected data, (2) cutoffs derived using the Youden Index for the contrast of AD dementia vs all non-AD disorders in one cohort and applied to the others, (3) cutoffs using SUVRs closest to 95% sensitivity and 95% specificity for the contrast AD dementia vs controls in 1 cohort and applied to the 2 other cohorts, and (4) patients with Aβ-negative AD dementia. To identify factors associated with tau negativity in AD dementia and tau positivity in non-AD neurodegenerative disorders, we performed bivariate binary logistic regression models with [
18 F]flortaucipir status (determined using the mean+[2 × SD] in controls approach) in the temporal meta-ROI as dependent variable and age, sex, apolipoprotein E (APOE) ε4 status, Aβ status (only in non-AD analyses), and Mini-Mental State Examination (MMSE) score as predictors. Additionally, we performed multivariable binary logistic regression models using observed data only and multiple imputations (with 25 multiple imputations and 40 iterations) to account for missing data. Test assumptions for these models were met, as the dependent variable is binary, observations are independent, and there is limited collinearity among independent variables.
Furthermore, we performed receiver operating characteristic analyses to generate the area under the curve (AUC) for both AD dementia and MCI due to AD against non-AD neurodegenerative disorders. 
Results
Participants
The study included 719 participants, including 179 with AD dementia, 254 with non-AD neurodegenerative disorder The figure shows the volume-weighted average of the temporal meta-ROI, which includes the bilateral entorhinal, amygdala, fusiform, and inferior and middle temporal cortices. The dots indicate individuals within the diagnostic groups. Box and whisker plots are only shown for groups with at least 10 participants. The box ranges from the first to the third quartile, the vertical line represents the median of the diagnostic group, and the whiskers indicate the range from the minimum to quartile 1 and from quartile 3 to the maximum, excluding outliers. Outliers were defined as standardized uptake value ratios (SUVRs) less than quartile 1 or greater than quartile 3 by more than 1.5 times the interquartile range, and were shown as separate plotted points. The dotted line represents the cutoff (SUVR: 1.34, defined using the mean +2 ×SD in all controls). Aβ indicates amyloid-β. 25 ; all post-hoc pairwise comparisons: P < .001), higher in MCI due to AD compared with non-AD neurodegenerative disorder and control groups (all post-hoc pairwise comparisons: P < .001), and did not differ significantly between non-AD neurodegenerative disorders and controls (P range, .12-.91). In 6 participants with autopsy data, the clinical diagnoses of AD dementia (n = 1) or a non-AD neurodegenerative disorder (n = 5) were neuropathologically confirmed.
There AD Dementia vs Non-AD Neurodegenerative Disorders Figure 1 shows the mean temporal meta-ROI and Figure 2 shows the whole-brain voxelwise [ Figure 3C ). When comparing AD dementia with specific non-AD clinical syndromes, diagnostic performance within the temporal meta-ROI was consistent with results in the combined non-AD neurodegenerative disorders group, except for the lower specificity in the dementia with Lewy bodies (66.7% [95% CI, 44.7%-84.4%]) and semantic variant primary progressive aphasia (63.6% [95% CI, 30.8%-89.1%]) groups ( Table 3) . Across all ROIs, [ a Diagnostic test measures were obtained using a threshold derived in all controls (n = 160) (mean +2×SD) and applied to all participants with AD dementia (n = 179) and non-AD (n = 254) in the study, the Youden Index (55 with AD dementia vs 90 controls) in the Seoul cohort applied to participants with AD dementia (n = 124) and non-AD disorders (n = 165) from UCSF and BioFINDER cohorts, and the Youden Index (52 with AD dementia vs 66 controls) in BioFINDER cohort applied to participants with AD dementia (n = 127) and non-AD disorders (n = 181) from UCSF and Seoul cohorts.
b Volume-weighted average of bilateral entorhinal, amygdala, fusiform, and inferior and middle temporal cortices. 7, 19, 26 c Based on a neuropathological staging system of neurofibrillary tangle pathology proposed by Braak and Braak. 31 Stages I and II include (trans)entorhinal regions; III and IV, limbic areas; and V and VI, neocortical tangle pathology.
MCI Due to AD vs Non-AD Neurodegenerative Disorders
The discriminative accuracy of [
18 F]flortaucipir in the MCI due to AD vs non-AD neurodegenerative conditions group was lower compared with the AD dementia group ( Figure 3 Figure 3D ). Table 3 shows the diagnostic performance for distinguishing MCI due to AD from the different non-AD neurodegenerative conditions.
Factors Contributing to Flortaucipir Status
Bivariate binary logistic regression models in patients with AD dementia showed that tau positivity in the temporal meta-ROI was associated with lower odds for age (odds ratio a Diagnostic test measures of the temporal meta-ROI were obtained using a threshold derived in all controls (mean +2 × SD) and applied to all participants with AD dementia and non-AD disorders in the study, and all participants with MCI due to AD and those with non-AD disorders in the study.
b Includes behavioral variant frontotemporal dementia, nonfluent variant primary progressive aphasia, and semantic variant primary progressive aphasia.
c Includes Parkinson disease with and without cognitive impairment, progressive supranuclear palsy, dementia with Lewy bodies, and corticobasal syndrome.
d Parkinson disease plus objective cognitive impairment (ie, MCI or dementia).
e The positive likelihood ratio in patients with progressive supranuclear palsy or corticobasal syndrome could not be calculated due to 100% specificity rates. 
Research Preliminary Communication
Accuracy of [ 18 F]flortaucipir PET for Alzheimer Disease vs Other Neurodegenerative
Flortaucipir PET vs Aβ Status
Although PET and CSF Aβ measures had 100% sensitivity in this study based on our definition of (Aβ-positive) AD dementia according to NIA-AA criteria, 2, 16 there is a potential lack of specificity as the prevalence of Aβ positivity is 20% to 40% in healthy elderly and non-AD populations. In the AD dementia group, approximately 10% were classified as tau negative, which was associated with older age and higher MMSE scores (eTable 13 in Supplement 1). Certain elderly individuals may develop clinical AD dementia in the presence of a lower tau burden due to age-related reductions in cognitive reserve and/or the development of multiple comorbid pathologies. 25, 37 Higher MMSE scores (ie, better general cognitive performance) indicate that patients in less advanced stages of AD dementia may not have accumulated sufficient tau to exceed the threshold, which is in line with lower rates of tau positivity in MCI due to AD compared with AD dementia (Figure 1 ). Another possible explanation for the absence of [ 18 F]flortaucipir signal is that Aβ was present as comorbid pathology in addition to a primary pathology (eg, hippocampal sclerosis, vascular lesions, or argyrophilic grain disease) that is typically not associated with AD-like tauopathy.
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Although specificity of [ 18 F]flortaucipir was high, about 5% to 10% of patients with a non-AD neurodegenerative disorder were classified as tau positive. The rate of Aβ positivity in the whole non-AD disorder group was 23.8%, which is in line with prevalence estimates of Aβ positivity in this age range in normal populations and non-AD syndromes. 3, 4 A proportion of the tau-positive cases may have been clinically misdiagnosed as having a non-AD disorder, with AD as underlying pathological substrate for their symptoms. Alternatively, paired helical filament-tau may have been present as a secondary pathology whereas the clinical syndrome was driven by non-AD pathologies. In this study, the strongest predictor for tau positivity in non-AD cases was Aβ positivity (eTable 13 in Supplement 1). This was observed across all non-AD neurodegenerative disorders, but was especially pronounced in the Lewy body dementia group. In line with neuropathological data, roughly 10% of patients with Aβ-negative Lewy body dementia were tau positive, while more than half of Aβ-positive patients were also tau positive (Figure 1 ; eFigure 3 in Supplement 1).
39
Another explanation for tau-positive non-AD cases is that [ 18 F]flortaucipir may not only bind to paired helical filaments of tau, but also weakly to other targets like straight or coiled filaments associated with non-AD tauopathies, TAR DNAbinding protein 43, monoamine oxidase B, or vascular lesions. 6 However, the mean SUVR images indicate that, although there may occur some binding in non-AD tauopathies and other proteinopathies, the regional distribution of [ 18 F]flortaucipir uptake at a group level clearly differentiates AD from non-AD neurodegenerative disorders (Figure 2 ). There were some individual exceptions, including 3 patients diagnosed as having semantic variant primary progressive aphasia (typically caused by TAR DNA-binding protein 43 type-C pathology) with strongly elevated neocortical [ Recently, an NIA-AA research framework was proposed that defines AD as a biological entity (ie, presence of Aβ plaques and tau neurofibrillary tangles) rather than a clinical syndrome. 16 Accordingly, irrespective of cognitive status (ie, cognitively normal or dementia) or degree of neurodegeneration, individuals with abnormal Aβ biomarkers have "Alzheimer pathological changes," and if these persons additionally harbor tau pathology, they have "Alzheimer disease." Positivity on [
18 F]flortaucipir PET (and/or CSF phosphorylated-tau) is required to meet criteria for AD, and-given its high specificity-tau PET will consequently play a major role in the classification of participants in research studies and enrollment in clinical trials. The cutoffs derived using standard threshold approaches yielded lower sensitivity at the MCI stage of AD and only few cognitively normal individuals were considered tau positive. This might be a limitation for investigating AD in prodromal or preclinical stages, although eTable 9 in Supplement 1 indicates that the sensitivity can be improved by lowering cutoffs. Another topic for future investigation is whether and how [ 
Limitations
This study has several limitations. First, there is a potential selection bias because participants were recruited from academic memory disorder clinics and had already established diagnoses at time of [ are assessed simultaneously. This caveat could potentially have resulted in an overestimation of the test sensitivity and specificity. Second, the clinical diagnosis served as reference standard, as there were only limited (n = 6 cases) autopsy data available. Future studies on clinicopathological relationships are essential, especially in tau-negative AD dementia and tau-positive non-AD disorders. Third, there is currently no consensus on the optimal methodology for determining tau positivity. As visual read metrics still need to be developed, the analyses were based on dichotomous classification (positive/negative) applying thresholds to quantitative tau PET. Discriminative accuracy was consistent across methods and ROIs, however, and thresholds for tau positivity were comparable with an independent study. 7 Fourth, the multicenter approach has some inherent disadvantages related to lack of harmonization of both clinical and neuroimaging data acquisition. This could also be considered an advantage in terms of generalizability, as the consistency of results between sites supports the robustness of the findings. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Note that several studies [6] [7] [8] [9] [10] have shown high (~90%) concordance between PET and CSF for determining A -positivity. 
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